ClinicalTrials.gg
Active, not recruitingNCT06712992Updated Mar 12, 2025

Electromyographic Response to TsDcs in CNSLBP

An interventional study of Trans-spinal Direct Current Stimulation and Conventional Exercises in Low Back Pain, sponsored by German International University. Active, not recruiting at 2 sites in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by German International University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as active, not recruiting.
  • Registered 6 months after the study started (first participant enrolled May 2024, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies in Low Back Pain with a site in Egypt — 43 open to participants now, 44 under way, none of them phase 3. Low Back Pain · Egypt.

Planned enrollment
68th of 90
40 · median 60
Started
2024
with 27 others
No phase
88 of 121
32 open now
Primary completion
2025-04
later than 16 of 43 live
Registered
71st of 121
by date

Among the 121 studies in Low Back Pain with a site in Egypt, this one is the 68th largest by planned enrollment of the 90 interventional ones that give a count, is one of 28 that started in 2024, is one of 88 with no phase, reaches primary completion later than 16 of the 43 other live ones, and was the 71st registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

43 of the 121 studies in Low Back Pain with a site in Egypt are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Low Back Pain with a site in Egypt, or all of them as a file.
02

Study summary

The purpose of this randomized, double-blinded, sham-controlled study is to investigate the efficacy of trans-spinal direct current stimulation on pain level, quality of life, and electromyographic nociceptive flexion reflex in patients with non-specific chronic low back pain.

03

Conditions studied

  • Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals of both sexes.
  • Age 18-60 years old.
  • Chronic non-specific low back pain according to the most recent guidelines for the diagnosis and management of NSLPB come from the American College of Physicians and was published in 2017. According to these guidelines, the diagnosis of chronic NSLBP should be made based on the following criteria:
  • Chronic low back pain, defined as pain lasting for more than 12 weeks.
  • No specific identifiable cause of pain(e.g. infection, , fracture, inflammatory disorder).
  • No radicular symptoms(e.g. pain radiating down the leg).
  • No significant neurological deficits or findings on physical examination(e.g. loss of reflexes or muscle strength).

Exclusion criteria

Exclusion Criteria:

  • Previous fractures and/or surgery in the vertebral spine.
  • Neuropathic pain extending along the lower limb due to nerve root compression.
  • History of spine trauma or fracture.
  • Implanted pacemakers.
  • Pregnancy.
  • .
  • Systemic musculoskeletal diseases.
  • Epilepsy.
  • History of psychiatric disorders.
  • Obesity
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Trans-spinal direct current stimulation group

    Patients in this group will receive Conventional Exercises in addition to tsDCS. We will apply a current density of 0.035 mA/cm2 and will deliver a total charge density of 42.8 mC/cm2, below the threshold values reported for tissue damage. For tsDcs, At the onset of tsDCS, the current will be increased for 30 s, and at the offset, it will be decreased for 30 s in a ramp-like manner. Participants will receive three sessions of treatment per week for four weeks, with a total of twelve sessions.

    Device: Trans-spinal Direct Current Stimulation · Other: Conventional Exercises

  • Sham comparator
    Sham Trans-spinal direct current stimulation group

    Patients in this group will receive Conventional Exercises in addition to SHAM tsDCS. For a sham tsDCS, the current will be ramped up for 30 seconds turned on for 5 s and then turned off in a ramp shaped fashion, thus inducing skin sensations indistinguishable from anodal tsDCS. This method was shown to achieve a good level of blinding among sessions. Participants will receive three sessions of treatment per week for four weeks, with a total of twelve sessions.

    Other: Conventional Exercises · Drug: SHAM Trans-spinal Direct current stimulation

Interventions

  • DeviceTrans-spinal Direct Current Stimulation

    Physiomed- IONOSON-Expert, Germany will be used to deliver SHAM direct current, The Physiomed- IONOSON-Expert, Germany is Two-channel electrotherapy including 21 currents, including direct current. The tsDCS electrodes will be rectangular pieces of saline-soaked synthetic sponge (7 × 8 cm, 56 cm2), to minimize chemical reactions at the electrode-skin interface. The anode will be placed over the spinous process of the eighth thoracic vertebra (T8) and the cathode will be placed on the second lumbar vertebra (L2) according to a modeling study which demonstrated that this configuration had a relevant impact on the distribution of the induced electric field (EF) in the lumbosacral spinal cord for the efficacy of tsDCS.

  • OtherConventional Exercises

    1. Isometric exercises of spine * Hollowing in abdominals. * Isometric for back extensors. 2. Bridging exercises. 3. Graded active flexion exercises of spine 4. Graded active extension exercises of spine

  • DrugSHAM Trans-spinal Direct current stimulation

    For a sham tsDCS, the current will be ramped up for 30 seconds turned on for 5 s and then turned off in a ramp shaped fashion, thus inducing skin sensations indistinguishable from anodal tsDCS. This method was shown to achieve a good level of blinding among sessions. These parameters for sham stimulation were chosen based on previous reports that the perceived sensations on the skin, such as tingling, fade usually out in the first 30 s of TsDcs .

06

What researchers measure

Primary outcomes

  1. Changes in NPRS from baseline to four weeks

    An 11-point Numerical Pain Rating Scale (NPRS; 0= no pain, 10= maximum pain) will be used to assess the patients' pre and post treatment levels of back pain. The NPRS can be administered verbally (therefore also by telephone) or graphically for self-completion. Scores range from 0-10 points, with higher scores indicating greater pain intensity

    Time frame: Baseline and 4 weeks

Secondary outcomes

  1. Changes in Nociceptive Flexion Reflex (NFR) Threshold and area from baseline to 4 weeks

    The NFR threshold will be assessed as an objective measure of spinal nociceptive processing in adults with chronic non-specific low back pain (CNSLBP). The NFR threshold will be defined as the lowest stimulus intensity that elicits an NFR response.The NFR threshold and NFR area will be assessed before and after 4 weeks of trans-spinal direct current stimulation (tsDCS) plus exercise or sham stimulation plus exercise.

    Time frame: Baseline and 4 weeks

  2. Changes in PROMIS Global Health - 10 Survey from baseline to 4 weeks

    The Patient-Reported Outcomes Measurement Information System (PROMIS) is a comprehensive instrument designed to assess health-related quality of life across various domains. PROMIS GH-10, specifically, is tailored to measure global physical and mental health. It encompasses a range of items that evaluate general health perceptions, physical function, pain, fatigue, emotional distress, and social health. PROMIS GH-10 has been demonstrated to be reliable and valid for use in the general population and various specific conditions, such as low back pain.

    Time frame: Baseline and 4 weeks

07

Study locations

2 sites
  • Outpatient clinic of faculty of physical therapy, Ahram Canadian University
    Sixth of October, Giza 12611, Egypt
  • Outpatient clinical of faculty of physical therapy, Ahram Canadian University
    sixth of October, Giza 12611, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Apr 2025, 10 months after the start.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 10 months is close to that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Dec 3, 2024
StartActual
May 16, 2024
Primary completionEst.
Apr 1, 2025
CompletionEst.
Apr 10, 2025
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06712992
Lead sponsor
German International University
Responsible party
Ahmed Medhat Mahfouz Elgamal (Principal invistigator, Cairo University) — Principal investigator
First posted
Dec 3, 2024
Start date
May 16, 2024
Primary completion
Apr 1, 2025 (estimated)
Completion
Apr 10, 2025 (estimated)
Last update
Mar 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion